Institute for Asthma and Allergy

Recent papers from Institute for Asthma and Allergy

1. Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet · 2023
2. Oral deucrictibant for on-demand treatment of hereditary angioedema attacks: a phase 3, multicentre, randomised, double-blind, placebo-controlled crossover trialThe Lancet · 2026
3. Development and pilot validation of a chemiluminescence immunoassay for monitoring immunologic changes during peanut oral immunotherapy using sIgE/sIgG4 ratioFrontiers in Allergy · 2026
4. Sebetralstat for breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis in KONFIDENT-SJournal of Allergy and Clinical Immunology Global · 2026
5. Sebetralstat for on-demand treatment of hereditary angioedema: A pooled analysis of placebo-controlled clinical trialsWorld Allergy Organization Journal · 2026
6. Long-Term Integrated Safety and Efficacy of Garadacimab for Hereditary Angioedema ProphylaxisAdvances in Therapy · 2026
7. Post Hoc Analysis of Recombinant C1 Inhibitor Clinical Data Using Contemporary Endpoints for Hereditary AngioedemaAdvances in Therapy · 2026
8. Comparative Efficacy of Recombinant C1 Inhibitor Versus Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks: A Matching-Adjusted Indirect Treatment Comparison.2026
9. The 2025 WAO Guidelines for the classification, diagnosis, and treatment of hereditary angioedema, with consideration of worldwide disparitiesWorld Allergy Organization Journal · 2026
10. Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trialThe Lancet Haematology · 2026
11. An Open-Label Phase 1b/2 Trial of Navenibart, a Long-Acting Plasma Kallikrein Inhibitor for Hereditary AngioedemaJournal of Allergy and Clinical Immunology · 2026
12. Correction to: A Multicentric Clinical Study to Evaluate Pharmacokinetics, Efficacy, and Safety of Immune Globulin Subcutaneous 20% Weekly/Biweekly Dosing in Treatment-Experienced Patients and Loading/Weekly Maintenance Dosing in Treatment-Naïve Patients with Primary ImmunodeficiencyJournal of Clinical Immunology · 2026
13. Efficacy of Epinephrine Nasal Spray in the Treatment of UrticariaThe Journal of Allergy and Clinical Immunology In Practice · 2026
14. A Multicentric Clinical Study to Evaluate Pharmacokinetics, Efficacy, and Safety of Immune Globulin Subcutaneous 20% Weekly/Biweekly Dosing in Treatment-Experienced Patients and Loading/Weekly Maintenance Dosing in Treatment-Naïve Patients with Primary ImmunodeficiencyJournal of Clinical Immunology · 2025
15. Management of Wound Site InfectionsBolu Abant Izzet Baysal Universitesi Tip Fakultesi Abant Tip Dergisi · 2025
16. Vamp3/syntaxin 4 mediates the basolateral membrane fusion of TfR transcytosis across the BBB and is exploited by pathogenic Escherichia coliProceedings of the National Academy of Sciences · 2025
17. Prenatal Smoking Exposures and Epigenome-Wide Methylation in Newborn BloodEnvironmental Health Perspectives · 2025
18. Lower levels of senescence in human lung mesenchymal stromal cells compared with lung fibroblasts: implications for tissue regeneration in COPDAJP Lung Cellular and Molecular Physiology · 2025
19. Identification of an elusive SERPING1 deletion in a family with hereditary angioedema type I utilizing soft clippingFrontiers in Allergy · 2025
20. Generational shifts in atopic disease among immigrant families to North America from Southern IndiaJournal of Allergy and Clinical Immunology Global · 2025